| scholarly article | Q13442814 |
| P50 | author | Marco Marra | Q6757610 |
| Yussanne Ma | Q110944219 | ||
| P2093 | author name string | Stephen Yip | |
| Steven J M Jones | |||
| Yongjun Zhao | |||
| Richard Moore | |||
| Katayoon Kasaian | |||
| Yaoqing Shen | |||
| Cheryl Ho | |||
| Martin Jones | |||
| Diana N Ionescu | |||
| Howard Lim | |||
| Karen Mungall | |||
| Erin Pleasance | |||
| Janessa Laskin | |||
| Daniel J Renouf | |||
| Sophie Sun | |||
| Erica S Tsang | |||
| Andrew Mungall | |||
| Negar Chooback | |||
| P2860 | cites work | Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. | Q27851719 |
| Tracking genomic cancer evolution for precision medicine: the lung TRACERx study | Q28655985 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| The cancer genome | Q29547643 | ||
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| The BATTLE trial: personalizing therapy for lung cancer | Q34275011 | ||
| Clinical Implications of the Cancer Genome | Q34488700 | ||
| Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative | Q35680026 | ||
| Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers | Q36851421 | ||
| Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer | Q36899904 | ||
| Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial | Q37220383 | ||
| Implementing personalized cancer genomics in clinical trials | Q38102920 | ||
| Prioritizing targets for precision cancer medicine | Q38262620 | ||
| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial | Q38581287 | ||
| Defining actionable mutations for oncology therapeutic development. | Q38816901 | ||
| Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. | Q39640189 | ||
| Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer | Q42634827 | ||
| Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers | Q50539670 | ||
| Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. | Q51658537 | ||
| Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme | Q59654241 | ||
| High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial | Q62785349 | ||
| Recent clinical advances in lung cancer management | Q87355242 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | whole genome sequencing | Q2068526 |
| P304 | page(s) | a002659 | |
| P577 | publication date | 2019-02-01 | |
| P1433 | published in | Cold Spring Harbor molecular case studies | Q27726567 |
| P1476 | title | Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer | |
| P478 | volume | 5 |
Search more.